TGFβ-induced FOXS1 controls epithelial-mesenchymal transition and predicts a poor prognosis in liver cancer - Archive ouverte HAL
Cancers | Free Full-Text | The lncRNA H19-Derived MicroRNA-675 Promotes Liver Necroptosis by Targeting FADD
MicroRNAs in Animal Models of HCC
Stefano Caruso (@Stecarus) / Twitter
Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response - ScienceDirect
Stefano Caruso (@Stecarus) / Twitter
Functional genomics of solid tumors - FunGeST -
APSselect
The molecular road map of HCC
Germline and somatic DICER1 mutations in familial and sporadic liver tumors
BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA
Our Research
PPT - Disclosure PowerPoint Presentation, free download - ID:603758
Catching up with Stefano Caruso | Ice-dance.com
Functional genomics of solid tumors - FunGeST -
Deleting the β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth - ScienceDirect
Stefano Caruso - Wikipedia
BERENGERE OUINE | Institut Curie
Study Points Toward New Ways to Prevent Liver Cancer | Mirage News
Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity - Caruso - 2021 - Hepatology - Wiley Online Library
Deleting in vivo β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumors | bioRxiv
Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study
Chronic Alcohol Use : Genetic Variations Provide Protection from Liver Cancer | Université Paris Cité
Stefano Caruso (@Stecarus) / Twitter
Stefano Caruso (@Stecarus) / Twitter
Functional genomics of solid tumors - FunGeST -
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial - UROONCO Kidney Cancer
